Coherus Oncology, Inc. (CHRS)
NASDAQ: CHRS · Real-Time Price · USD
1.930
+0.110 (6.04%)
At close: Mar 9, 2026, 4:00 PM EDT
1.870
-0.060 (-3.11%)
After-hours: Mar 9, 2026, 6:33 PM EDT
Coherus Oncology Revenue
In the year 2025, Coherus Oncology had annual revenue of $42.17M, down -84.20%. Coherus Oncology had revenue of $12.75M in the quarter ending December 31, 2025, with 64.85% growth.
Revenue (ttm)
$42.17M
Revenue Growth
+59.81%
P/S Ratio
6.84
Revenue / Employee
$266,911
Employees
158
Market Cap
288.48M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 42.17M | -224.79M | -84.20% |
| Dec 31, 2024 | 266.96M | 9.72M | 3.78% |
| Dec 31, 2023 | 257.24M | 46.20M | 21.89% |
| Dec 31, 2022 | 211.04M | -115.51M | -35.37% |
| Dec 31, 2021 | 326.55M | -149.27M | -31.37% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Cellectis | 82.55M |
| OmniAb | 18.67M |
| Ovid Therapeutics | 6.61M |
| AC Immune | 5.48M |
| Silence Therapeutics | 559.00K |
| Abeona Therapeutics | 400.00K |
CHRS News
- 2 hours ago - Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 7 days ago - Coherus Oncology to Report Full Year and Fourth Quarter 2025 Financial Results on March 9, 2026 - GlobeNewsWire
- 14 days ago - Coherus Oncology to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 20 days ago - Coherus Oncology, Inc. Announces Closing of Public Offering of Common Stock - GlobeNewsWire
- 24 days ago - Coherus Oncology, Inc. Announces Pricing of Public Offering of Common Stock - GlobeNewsWire
- 7 weeks ago - Coherus Oncology, Inc. (CHRS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 2 months ago - Coherus Management to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 2 months ago - Coherus Oncology Announces Publication in Molecular Cancer Therapeutics Highlighting the Strong Pharmacology of Investigational CCR8 Antibody Tagmokitug (CHS-114) - GlobeNewsWire